<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sodium fluoride F18: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sodium fluoride F18: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sodium fluoride F18: Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="87031" href="/d/html/87031.html" rel="external">see "Sodium fluoride F18: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52871516"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>NaF Plus;</li>
<li>Osteovision</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F15404829"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Radiopharmaceutical</li></ul></div>
<div class="block doa drugH1Div" id="F15508818"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6e41a7c-edc7-4640-a258-58aa015ccc4a">Skeletal imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skeletal imaging: IV:</b> 8 to 12 mCi (300 to 450 MBq).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990854"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988147"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dop drugH1Div" id="F15508817"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6e41a7c-edc7-4640-a258-58aa015ccc4a">Skeletal imaging</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skeletal imaging:</b> IV: Weight-based doses (0.06 mCi/kg [2.1 MBq/kg]) ranging from 0.5 to 4 mCi (19 to 148 MBq) were reported in clinical experience.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51220154"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51220155"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F15508798"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">No adverse events have been reported at this time.</p></div>
<div class="block coi drugH1Div" id="F15404844"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F15404845"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cancer: Patients are exposed to some radiation during treatment; large cumulative amounts of radiation exposure may increase the risk of cancer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May localize in areas of bone turnover, including developing long bones. Children are more sensitive to radiation; therefore, the lowest radiation-absorbed dose should be utilized to minimize risk to the patient and provide quality imaging (Gelfand, 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special handling:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel (eg, wear waterproof gloves and use effective shielding). Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Absorbed radiation: Bone, bone marrow, and urinary bladder are target organs for high absorbed radiation doses. To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Imaging: Patients should void immediately before imaging the radioactivity in the lumbar spine or bony pelvis.</p></div>
<div class="block foc drugH1Div" id="F56324124"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, Intravenous:</p>
<p style="text-indent:-2em;margin-left:4em;">Generic: 10-200 mCi/mL (30 mL)</p></div>
<div class="block geq drugH1Div" id="F53040758"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52871517"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Osteovision: 300 mCi/mL (10 mL, 30 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10-200 MCI/ML (30 mL)</p></div>
<div class="block adm drugH1Div" id="F15508823"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: For IV administration. PET scan should begin 1 to 2 hours after administration. Wear waterproof gloves and use protective shielding when handling and administering sodium fluoride F18. To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours. See manufacturer's prescribing information for complete administration procedure.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Radiopharmaceutical; use appropriate precautions for handling and disposal.</b></p></div>
<div class="block admp drugH1Div" id="F52618191"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: For IV administration. See manufacturer's labeling for complete administration procedure. Wear waterproof gloves and use protective shielding when handling and administering sodium fluoride F18. PET scan should begin 1 to 2 hours after administration. To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Radiopharmaceutical; use appropriate precautions for handling and disposal.</b></p></div>
<div class="block use drugH1Div" id="F15404831"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Skeletal imaging:</b> Imaging agent used in conjunction with positron emission tomography (PET) for imaging of bone to define areas of altered osteogenic activity</p></div>
<div class="block mst drugH1Div" id="F15404826"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F15594464"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F15594462"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F15404833"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted. All radiopharmaceuticals have the potential to cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F15404838"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for adverse reactions in the nursing infant, breast-feeding is not recommended. The manufacturer recommends interrupting breast-feeding for ≥24 hours to minimize radioactivity exposure and risk to the infant.</p></div>
<div class="block dic drugH1Div" id="F15508822"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">To minimize the radiation-absorbed dose to the bladder, encourage patients to drink ≥500 mL of fluid immediately before and after administration and to void 30 minutes after administration and frequently over the next 12 hours.</p></div>
<div class="block pha drugH1Div" id="F15508807"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Fluoride F18 ion accumulates in the skeleton with increased deposition in the vertebrae and pelvis to define areas of abnormal osteogenic activity.</p></div>
<div class="block phk drugH1Div" id="F15508809"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Blood, bone; only ~10% of dose remains in blood 1 hour after administration</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Biexponential: First phase: 0.4 hours; Second phase: 2.6 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (≥20% within the first 2 hours after administration)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58209222"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cisnaf</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-22471910">
<a name="22471910"></a>Bruijnen ST, van der Weijden MA, Klein JP, et al. Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study. <i>Arthritis Res Ther</i>. 2012;14(2):R71.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-fluoride-f18-drug-information/abstract-text/22471910/pubmed" id="22471910" target="_blank">22471910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21233182">
<a name="21233182"></a>Gelfand MJ, Parisi MT, Treves ST, et al, "Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines," <i>J Nucl Med</i>, 2011, 52(2):318-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-fluoride-f18-drug-information/abstract-text/21233182/pubmed" id="21233182" target="_blank">21233182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21051652">
<a name="21051652"></a>Segall G, Delbeke D, Stabin MG, et al, "SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0," <i>J Nucl Med</i>, 2010, 51(11):1813-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sodium-fluoride-f18-drug-information/abstract-text/21051652/pubmed" id="21051652" target="_blank">21051652</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sodium fluoride [prescribing information]. Orlando, FL: Jubilant Radiopharma; February 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 87030 Version 58.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
